ArticleTranslational cancer research2022

Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report.

Jingyu Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.